NEW YORK, July 9, 2026 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Larimar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 29, 2025, Larimar issued a press release announcing data from an ongoing long-term open-label study evaluating daily subcutaneous injections of nomlabofusp in participants with Friedreich’s Ataxia. Although Larimar characterized the data as “positive”, the press release disclosed that anaphylaxis or a severe allergic reaction was reported in seven participants.
On this news, Larimar’s stock price fell $1.72 per share, or 33.66%, to close at $3.38 per share on September 29, 2025.
Then, on June 29, 2026, Larimar released new data from its ongoing open-label study and confirmed the submission of the first section of its rolling Biologics License Application (“BLA”) seeking accelerated approval for nomlabofusp as a treatment for Friedreich’s ataxia. Although the press release characterized the data as “positive”, it revealed an ongoing safety signal, with anaphylaxis reported in 10 of 43 patients.
On this news, Larimar’s stock price fell $0.46 per share, or 12.57%, to close at $3.20 per share on June 29, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-larimar-therapeutics-inc—lrmr-302822376.html
SOURCE Pomerantz LLP
